Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
1.069
-0.061 (-5.41%)
Dec 3, 2024, 1:37 PM EST - Market open
Rallybio Employees
Rallybio had 43 employees as of December 31, 2023. The number of employees increased by 2 or 4.88% compared to the previous year.
Employees
43
Change (1Y)
2
Growth (1Y)
4.88%
Revenue / Employee
$13,907
Profits / Employee
-$1,557,512
Market Cap
44.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Omega Therapeutics | 94 |
| Xilio Therapeutics | 73 |
| AN2 Therapeutics | 41 |
| Gain Therapeutics | 32 |
| Outlook Therapeutics | 24 |
| BioVie | 14 |
| Serina Therapeutics | 11 |
RLYB News
- 1 day ago - Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
- 6 days ago - Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
- 7 days ago - Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Business Wire
- 8 days ago - Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire
- 12 days ago - Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 - Business Wire
- 26 days ago - Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire
- 5 weeks ago - Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
- 2 months ago - Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - Business Wire